Ask Warren

Aimed Bio

0009K0 · KOSDAQ · ₩0009K0 · 에임드바이오

₩20,850▲ ₩300 (1.46%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −52.61%
Market cap
₩1.4T
Enterprise value
₩1.3T
P/E
270.4×
P/B
6.6×
Dividend yield
0.0%
ROE
2.5%
Net margin
10.6%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−74.0% from the high

₩17,400Today: ₩20,550 – ₩21,400₩80,200

Returns

  • 1W−5.2%
  • 1M−6.7%
  • 3M+15.0%
  • 6M−57.2%
  • YTD−63.8%
  • 1Y—
Volume today
113,975
0.8× the 20-day average
Traded today
₩2.4B
Listed shares
65,137,661
EPS (12 months)
₩77
Earnings yield 0.4%
SellBuy
AI research · InitiationAimed Bio: High-Margin Earnings on a Small Base, With a Share Price Well Above the Model EstimateThe filed numbers show a profitable, cash-generating company with very little debt, but returns on equity are low at 2.5% and valuation multiples are high against both peers and the model estimate.Read the full report →IPOListed Dec 4, 2025 at ₩11,000IPO details →

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

42Quiet
  • BuzzQuietBuzz 42 of 100 (50 is a normal day for this stock).
  • SentimentPositiveNews: Milestone news is positive, but the management filing is unclear. Community: 0 bullish, 0 bearish posts this week.
  • MomentumFlat-2.6% over the last month; the price is below its 20-day average.
  • News impactSome2 news items and filings in two weeks; 0 rated high impact, 2 medium.

Signals describe activity, not recommendations. Not financial advice.

Leveraged ETF flows

Estimated leveraged-ETF rebalance on Oct 28: buy ₩2.3B at the close (71.8% of 20-day average trading value)

Sep 29Last 20 trading days (% of average trading value)Oct 28

On its 26 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 54.0% of trading value and pointed the same way 20 of 26 times.

  • 2× KODEX KOSDAQ150 Leverage ₩2B
  • -1× KODEX KOSDAQ150 Futures Inverse ₩113M
  • 2× TIGER KOSDAQ150 Leverage ₩103M
  • 2× RISE KOSDAQ150 Futures Leverage ₩19M
  • -1× TIGER KOSDAQ150 Futures Inverse ₩3.7M

Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.

Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.

Estimate based on ETF size and daily moves; actual trades may differ.

ETFs holding this

All ETFs →

Held by 11 funds.

Estimated from the funds' index or underlying stock.

Futures and options

All stock futures →

Futures (2026-11): 20,900

Basis +0.24% · implied rate +5.8%

Open interest 1,269 contracts

Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.

Aimed Bio stock overview

Aimed Bio (에임드바이오, KRX: 0009K0) is listed on KOSDAQ, in the Biotech & Pharma sector. AimedBio is a Korean biotech company developing antibody-drug conjugate (ADC) cancer therapies, using patient-derived cell and xenograft models to select targets and antibodies. Its shares closed at ₩20,850 on Oct 28, 2026, up 1.46% on the day, giving it a market value of ₩1.4T.

Key facts

Market cap
₩1.4T
Sector
Biotech & Pharma
Latest price change
+1.46%
As of
Oct 28, 2026
Main business
AimedBio is a Korean biotech company developing antibody-drug conjugate (ADC) cancer therapies, using patient-derived cell and xenograft models to select targets and antibodies.

Quick answers about Aimed Bio

What does Aimed Bio do?
AimedBio is a Korean biotech company developing antibody-drug conjugate (ADC) cancer therapies, using patient-derived cell and xenograft models to select targets and antibodies. It was spun off from Samsung Seoul Hospital and generally out-licenses its preclinical and early-clinical ADC candidates to global pharmaceutical partners, such as Biohaven, SK Plasma and Boehringer Ingelheim, while relying on global CDMO partners for clinical-grade manufacturing.
What is the market cap of Aimed Bio?
The market capitalisation of Aimed Bio was ₩1.4T at the close on Oct 28, 2026.
Who are the largest shareholders of Aimed Bio?
According to the latest official filings, the largest reported holders are Nam Do-hyeon (35.28%, as of Dec 10, 2025); SMB Investment Partners (15.09%, as of Dec 22, 2025); Interbest (10.59%, as of Mar 17, 2026).
When is the next earnings report from Aimed Bio?
Korean companies rarely announce results dates in advance. Based on when Aimed Bio filed the same report in past years, its next 3q results is expected around Dec 10, 2026.
Does the National Pension Service own Aimed Bio?
Yes. The National Pension Service held 0.03% of Aimed Bio shares as of Dec 31, 2025.

Company profile

AimedBio is a Korean biotech company developing antibody-drug conjugate (ADC) cancer therapies, using patient-derived cell and xenograft models to select targets and antibodies. It was spun off from Samsung Seoul Hospital and generally out-licenses its preclinical and early-clinical ADC candidates to global pharmaceutical partners, such as Biohaven, SK Plasma and Boehringer Ingelheim, while relying on global CDMO partners for clinical-grade manufacturing.

Written by AI from the company's latest annual report.

Korean name
에임드바이오
Sector
Biotech & Pharma
Themes
Biotech (new drugs)
CEO
허남구
Founded
Aug 2018
Listed
Dec 2025
Listed shares
65,137,661
Fiscal year ends
Month 12
Website
www.aimedbio.com

Similar companies

Recent news

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: Aimed Bio / 에임드바이오 / 0009K0 / KRX:0009K0

Source: KRX statistical information